Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab - Basho, R K; Gilcrease, M; Murthy, R K; Helgason, T; Karp, D D; Meric-Bernstam, F (JAMA Oncol, 2017)